• 30% Calcium Hydroxylapatite (CaHA): Synthetic microspheres (25-45 μm diameter).

• 70% Gel Carrier: Sodium Carboxymethylcellulose (CMC), highly hydrated.

• Degradation Pathway: Phagocytosis via macrophages. Non-inflammatory.

• Elastic Modulus (G’): > 800 Pa. High tissue lifting capacity.

• Complex Viscosity (η*): Provides zero migration post-placement.

• pH Balance: 7.0 – 7.4. Isotonic to human tissue.

Clinical Trial Outcomes

Kquality-assured. Double-blind, randomized, multicenter study (n=245).

Clinical Experience & Direct Observations

Reference Literature

[1] Journal of Clinical and Aesthetic Dermatology (2024): Neocollagenesis and efficacy of 30% CaHA implants. PMID: 34910244.

[2] Device Registry: Volassom Registration Data & Biocompatibility Compliance.

Strict Medical Disclaimer

This technical specification is intended strictly for licensed medical professionals. Volassom is contraindicated for patients with severe allergies, bleeding disorders, or hypersensitivity to CaHA. Not approved for intramuscular, intravascular, or lip mucosal injection. Individual physiological responses, including longevity and collagen generation, are highly variable.